Johnson & Johnson on Tuesday reported $100 million in first-quarter sales of its Covid-19 vaccine that’s on hold in the U.S. while U.S. health regulators investigate a rare blood-clotting issue.
In releasinging its first-quarter financial results, the company also reported earnings and revenue that beat Wall Street’s expectations.
Here’s how J&J did compared with what Wall Street expected, according to average estimates compiled by Refinitiv:
- Adjusted EPS: $2.59 per share versus $2.34 expected.
- Revenue: $22.32 billion versus $21.98 billion expected.
J&J’s financial results come as the company’s Covid-19 vaccine has been put on pause in the United States after six women developed a rare but potentially life-threatening blood clotting disorder that left one dead and one in critical condition.
This is a developing story. Please check back for updates.